ArticleImmunoHorizons2025
Deficiency of interleukin-1 receptor antagonist aggravates Citrobacter rodentium infection in mice.
Article in ImmunoHorizons, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The interleukin-1 receptor (IL-1R) plays an important role in mediating the inflammatory responses against pathogens. However, it is not clear whether a sustained IL-1R signaling following the loss of its endogenous inhibitor, IL-1R antagonist (IL-1RA), could improve mucosal immunity against the murine enteropathogen, Citrobacter rodentium. At basal levels, IL-1RA-deficient (IL1raKO) mice displayed an elevated inflammatory tone as indicated by their higher levels of circulating neutrophils, and the inflammatory marker, lipocalin-2, in both systemic and luminal contents. We reasoned that the heightened inflammatory tone of IL1raKO mice may be beneficial in clearing C. rodentium efficiently, but such was not the case. Oral challenge of C. rodentium (1 × 109 colony-forming units/mouse) resulted in luminal colonization, which peaked at day 7 postinfection, in both wild-type and IL1raKO mice. However, IL1raKO mice displayed a higher C. rodentium burden, and exacerbated colonic inflammation and hyperplasia. The aggravated infection in IL1raKO mice was corroborated using in vivo imaging of mice infected with a bioluminescent strain of C. rodentium. However, IL1raKO mice do not display any defect in their neutrophils with respect to their recruitment to the inflamed gut, generation of neutrophil extracellular traps and reactive oxygen species, or their ability to kill C. rodentium in vitro. In contrast, the macrophages of IL1raKO mice were able to upregulate more inducible nitric oxide synthase and produce more nitrite that wild-type macrophages; however, the former was less effective in mediating killing of C. rodentium in vitro. Together, our results suggest that IL-1RA plays a protective role in combating enteropathogen infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.